Free Trial
NASDAQ:CRBU

Caribou Biosciences Q3 2024 Earnings Report

Caribou Biosciences logo
$2.10 +0.15 (+7.69%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$2.06 -0.04 (-1.67%)
As of 07:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
$2.02 million
Expected Revenue
$3.37 million
Beat/Miss
Missed by -$1.35 million
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
12:30PM ET

Upcoming Earnings

Caribou Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025

Caribou Biosciences Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
CRBU Caribou Biosciences, Inc. - Seeking Alpha
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU), a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

View Caribou Biosciences Profile

More Earnings Resources from MarketBeat